Today: 24 March 2026
Subscribe
Browse Category

Stock Market 2 January 2026

Uber stock rises as UK VAT ‘taxi tax’ takes effect; what investors watch next

Uber stock rises as UK VAT ‘taxi tax’ takes effect; what investors watch next

Uber shares rose 0.9% to $82.48 Friday after Britain barred London private-hire firms from using a VAT scheme, a move expected to raise £700 million annually. Uber rewrote contracts outside London to shift VAT responsibility to drivers, most of whom fall below the registration threshold, the Guardian reported. Lyft gained 1.6% and DoorDash slipped 1.5% in U.S. trading.
2 January 2026
··
Liquidia stock drops 8% today as put-option hedging spikes — what’s next for LQDANEW YORK, Jan 2, 2026, 14:24 ET — Regular session

Liquidia stock drops 8% today as put-option hedging spikes — what’s next for LQDANEW YORK, Jan 2, 2026, 14:24 ET — Regular session

Liquidia shares fell about 8% Friday, closing at $31.70 after swinging between $30.76 and $34.97 on heavy volume. Options trading showed a surge in put buying, with 15,696 contracts traded, 56% above normal. The drop outpaced biotech peers as investors watched for updates on the company’s patent dispute over Yutrepia and its next earnings report, expected March 18.
2 January 2026
···
Applied Digital stock jumps 15% today as ChronoScale spinoff plan and Jan. 7 earnings come into focus (APLD)

Applied Digital stock jumps 15% today as ChronoScale spinoff plan and Jan. 7 earnings come into focus (APLD)

Applied Digital Corp shares rose 15.4% to $28.29 Friday after announcing plans to spin out its cloud business and merge it with EKSO Bionics to form ChronoScale, an AI-focused platform. The company’s fiscal Q2 results are due Jan. 7. Applied Digital will own about 97% of ChronoScale if the deal closes. The stock outperformed major indexes and sector peers.
2 January 2026
···
AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie shares rose 0.2% to $228.95 after Ironwood Pharmaceuticals, its Linzess partner, raised 2026 U.S. net sales guidance and cut the drug’s list price effective Jan. 1. Ironwood shares jumped 29.5%. Ironwood now expects 2026 Linzess U.S. net sales of $1.125–$1.175 billion, up from 2025’s $860–$890 million forecast. Wall Street trading was muted as investors awaited U.S. labor data and watched for broader drug pricing moves.
2 January 2026
···
Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

Pfizer shares rose 0.8% to $25.09 Friday amid renewed focus on U.S. drug pricing after reports of 2026 list-price hikes, including a 15% increase for its COVID-19 vaccine. A Reuters report said Pfizer will lead price increases on about 80 drugs, though most hikes are under 10%. Investors await Pfizer’s next quarterly update on February 3. Trading volume reached about 20.7 million shares.
2 January 2026
··
Wells Fargo stock rises today as traders eye jobs report, big-bank earnings kickoff

Wells Fargo stock rises today as traders eye jobs report, big-bank earnings kickoff

Wells Fargo shares rose 1.2% to $94.35 in early afternoon New York trading Friday, moving between $92.81 and $94.43. The SPDR S&P Bank ETF edged up 0.3%, while the broader financial sector slipped. Investors are watching for the Jan. 9 U.S. jobs report and Wells Fargo’s Jan. 14 earnings. The Fed has cut rates at its last three meetings, with futures showing a 50% chance of another cut in March.
2 January 2026
··
Camtek stock jumps 8% today as chip-equipment rally lifts CAMT; traders eye Fed, jobs data

Camtek stock jumps 8% today as chip-equipment rally lifts CAMT; traders eye Fed, jobs data

Camtek shares jumped 8.1% to $115 in Friday afternoon trading, after swinging between $108.90 and $116. Chip stocks led Wall Street gains, with the Philadelphia SE Semiconductor index up 3.4% while broader markets stayed flat. Investors are watching next week’s U.S. labor data and upcoming chip earnings. Camtek last posted record quarterly revenue of $126 million in November.
2 January 2026
··
Silver price stock today: SLV ticks higher as bullion firms, miners lag

Silver price stock today: SLV ticks higher as bullion firms, miners lag

Spot silver rose 1.8% to $72.51 an ounce by midday in New York, rebounding after hitting a record $83.62 earlier in the week. iShares Silver Trust gained 0.8% and Sprott Physical Silver Trust added 1.0%, while major U.S.-listed silver miners fell sharply. Pan American Silver dropped 3.8%, Hecla Mining slid 5.3%, and First Majestic Silver lost 6.4%.
2 January 2026
·······
Natural gas price today: Futures slip as Cheniere stock climbs on record U.S. LNG exports

Natural gas price today: Futures slip as Cheniere stock climbs on record U.S. LNG exports

U.S. natural gas futures slipped, with the February Henry Hub contract down 2.1 cents to $3.665 per mmBtu. Cheniere Energy shares rose 2.6% after data showed U.S. LNG exports hit a record 111 million metric tons in 2025. Gas storage fell by 38 bcf last week, remaining slightly above the five-year average. Traders await next week’s storage data and updated weather forecasts.
2 January 2026
···
1 … 677 678 679 680 681 … 1,360

Stock Market Today

  • Q4 Earnings Review: Corcept and Eli Lilly Highlight Mixed Results in Branded Pharmaceuticals
    March 23, 2026, 8:15 PM EDT. As Q4 earnings wrap up, branded pharmaceuticals show a mixed picture. Corcept Therapeutics (NASDAQ:CORT) posted an 11.1% revenue increase to $202.1 million but missed analyst expectations by 18.5%, leading to a 5% drop in its stock. In contrast, Eli Lilly (NYSE:LLY) delivered strong growth with revenue up 42.6% year-on-year, beating estimates by 7.4%, though its shares fell 9.2%. The sector faces challenges like patent cliffs and pricing pressures but benefits from advances in precision medicine and AI-driven drug development. Overall, the group missed revenue forecasts by 7.7%, with stocks declining 7.2% since earnings. Investors remain cautious amid regulatory scrutiny and competition from generics.
Go toTop